NMR-based metabolomics approach to target biomarkers for human prostate cancer

References

• Jemal A, Tiwari R, Murrary T et al. Cancer Statistics, 2004. CA Cancer J. Clin.54, 8–29 (2004).
   PubMed Web of Science ®Google Scholar
• Report of the Prostate Cancer Progress Review Group. Defeating Prostate Cancer: Crucial Directions for Research. National Cancer Institute, USA (1998).
   Google Scholar
• Raamsdonk LM, Teusink B, Broadhurst D et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol.19, 45–50 (2001).
   PubMed Web of Science ®Google Scholar
• Oliver S. Functional genomics: all the king’s horses and all the king’s men can put Humpty together again. Mol. Cell12, 1343–1344 (2003).
   Google Scholar
• Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers9, 1–31 (2004).
   PubMed Web of Science ®Google Scholar
• Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev. Mol. Diagn.6, 821–829 (2006).
   PubMed Web of Science ®Google Scholar
• Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics7, 1109–1123 (2006).
   PubMed Web of Science ®Google Scholar
• Pauling L, Itano HA Singer SJ et al. Sickle cell anemia a molecular disease. Science110, 543–548 (1949).
   PubMed Web of Science ®Google Scholar
• Pauling L, Robinson A, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl Acad. Sci.68, 2374–2376 (1971).
   PubMed Web of Science ®Google Scholar
• Durr R. Modern metabolic conrol-theory. 1. Fundamental theorems. Biochem. Arch.1, 239–247 (1985).
   Google Scholar
• de Hoffman E, Stroobant V. Mass Spectrometry: Principles and Applications John Wiley and Sons, Hoboken, NJ, USA (2001).
   Google Scholar
• Farrar T. Introduction to Pulse NMR Spectroscopy The Farragut Press, WI, USA (1997).
   Google Scholar
• Daviss B. Growing pains for metabolomics. Scientist19, 25–28 (2005).
   Web of Science ®Google Scholar
• Wishart DS, Tzur D, Knox C et al. HMDB: the Human Metabolome Database. Nucleic Acids Res.35, D521–D526 (2007).
   PubMed Web of Science ®Google Scholar
• Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics6, 4716–4723 (2006).
   PubMed Web of Science ®Google Scholar
• Fiehn O. Metabolomics – the link between genotypes and phenotypes. Plant Mol. Biol.48, 155–171 (2002).
   PubMed Web of Science ®Google Scholar
• Plumb R, Granger J, Stumpf C, Wilson ID, Evans JA, Lenz EM. Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences. Analyst128, 819–823 (2003).
   PubMed Web of Science ®Google Scholar
• Cheng LL, Burns MA, Taylor JL et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res.65, 3030–3034 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate30, 248–255 (1997).
   PubMed Web of Science ®Google Scholar
• Carroll P, Lee K, Fuks Z, Kantoff P. Cancer of the prostate. In: Cancer: Principle & Practice of Oncology. DeVita V, Hellman S, Rosenberg S (Eds). Lippincott Williams & Wilkins, PA, USA (2001).
   Google Scholar
• Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem. Sci.24, 68–72 (1999).
   PubMed Web of Science ®Google Scholar
• Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology59, 269–182 (2000).
   PubMed Web of Science ®Google Scholar
• Costello LC, Liu Y, Zou J, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J. Biol. Chem.274, 17499–17504 (1999).
   PubMed Web of Science ®Google Scholar
• Ishii K, Usui S, Sugimura Y et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int. J. Cancer92, 49–54 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett.494, 112–116 (2001).
   PubMed Web of Science ®Google Scholar
• Swanson MG, Zektzer AS, Tabatabai ZL et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn. Reson. Med.55, 1257–1264 (2006).
   PubMed Web of Science ®Google Scholar
• DeVita VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology Lippincott, Williams & Wilkins, PA, USA (2005).
   Google Scholar
• Tumors of the prostate. In: WHO Classification of Tumors. Eble N, Suater G, Epstein J (Eds). IARC Press, Lyon, France 159 (2004).
   Google Scholar
• Steiner H, Moser P, Hager M et al. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate58, 277–282 (2004).
   Google Scholar
• Djavan B, Ravery V, Zlotta A et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J. Urol.166, 1679–1683 (2001).
   PubMed Web of Science ®Google Scholar
• Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol.151, 1571–1574 (1994).
   PubMed Web of Science ®Google Scholar
• Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J. Urol.167, 2435–2439 (2002).
   PubMed Web of Science ®Google Scholar
• Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl Cancer Inst.90, 1230–1231 (1998).
   PubMedGoogle Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA281, 1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Gleason DF. Classification of prostatic carcinomas. Cancer Chemother. Rep.50, 125–128 (1966).
   PubMedGoogle Scholar
• Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol.111, 58–64 (1974).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst.90, 766–771 (1998).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Potters L, Blasko JC et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology58, 393–399 (2001).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol.18, 3352–3359 (2000).
   PubMed Web of Science ®Google Scholar
• Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J. Urol.167, 1231–1234 (2002).
   PubMed Web of Science ®Google Scholar
• Ransohoff DF, McNaughton Collins M, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am. J. Med.113, 663–667 (2002).
   PubMed Web of Science ®Google Scholar
• Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients’ preferences for the management of non-metastatic prostate cancer: discrete choice experiment. Br. Med. J.328, 382 (2004).
   PubMedGoogle Scholar
• Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology55, 323–327 (2000).
   PubMed Web of Science ®Google Scholar
• Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol.165, 119–125 (2001).
   PubMed Web of Science ®Google Scholar
• Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol.169, 517–523 (2003).
   PubMed Web of Science ®Google Scholar
• Akin O, Sala E, Moskowitz CS et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology239, 784–792 (2006).
   PubMed Web of Science ®Google Scholar
• Katz S, Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol. Clin. North Am.44, 723–734 (2006).
   Google Scholar
• Coakley FV, Kurhanewicz J, Lu Y et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology223, 91–97 (2002).
   Google Scholar
• Akin O, Hricak H. Imaging of prostate cancer. Radiol. Clin. North Am.45, 207–222 (2007).
   Google Scholar
• Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology198, 795–805 (1996).
   PubMed Web of Science ®Google Scholar
• Males RG, Vigneron DB, Star-Lack J et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med.43, 17–22 (2000).
   Google Scholar
• Scheidler J, Hricak H, Vigneron DB et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. Radiology213, 473–480 (1999).
   PubMed Web of Science ®Google Scholar
• Catton C, Milosevic M, Warde P et al. Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. Urol. Clin. North Am.30, 751–763 (2003).
   Google Scholar
• Pucar D, Shukla-Dave A, Hricak H et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy – initial experience. Radiology236, 545–553 (2005).
   Google Scholar
• Coakley FV, Teh HS, Qayyum A et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology233, 441–448 (2004).
   Google Scholar
• Squillaci E, Manenti G, Mancino S et al. MR spectroscopy of prostate cancer. Initial clinical experience. J. Exp. Clin. Cancer Res.24, 523–530 (2005).
   Google Scholar
• Averna TA, Kline EE, Smith AY, Sillerud LO. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. J. Urol.173, 433–438 (2005).
   PubMed Web of Science ®Google Scholar
• Kline EE, Treat EG, Averna TA, Davis MS, Smith AY, Sillerud LO. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J. Urol.176, 2274–2279 (2006).
   PubMed Web of Science ®Google Scholar
• Andrew E, Bradbury A, Eades R. Removal of dipolar broadening of nuclear mangetic resonance spectra of solids by specimen rotation. Nature183, 1802–1803 (1959).
   Web of Science ®Google Scholar
• Cheng LL, Lean CL, Bogdanova A et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn. Reson. Med.36, 653–658 (1996).
   PubMed Web of Science ®Google Scholar
• Cheng LL, Ma MJ, Becerra L et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc. Natl Acad. Sci. USA94, 6408–6413 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro-oncology2, 87–95 (2000).
   Google Scholar
• Swanson MG, Vigneron DB, Tabatabai ZL et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med.50, 944–954 (2003).
   PubMedGoogle Scholar
• Milkevitch M, Shim H, Pilatus U et al. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta1734, 1–12 (2005).
   Google Scholar
• Eaton JD, Perry MJ, Todryk SM et al. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther.8, 557–567 (2001).
   PubMed Web of Science ®Google Scholar